Previous close | 2.0000 |
Open | 2.0000 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 17.50 |
Expiry date | 2024-05-17 |
Day's range | 2.0000 - 2.0000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer Presented updat
SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2024 (the “Grant Date”), ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024. These inducement grants were granted